Jarushka Naidoo, MBBCh, MHS, Beaumont Hospital, Dublin, Ireland, gives an overview of a study investigating immune-related adverse events (AEs) associated with immune checkpoint inhibitor therapy for the treatment of non-small cell lung cancer (NSCLC). The study aimed to determine the proportion of patients with lung cancer who developed multisystem immune-related AEs, to identify unique features in these patients and to investigate associations with patient outcomes. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.